• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cellect Biotechnology Ltd.

    11/12/21 2:20:55 PM ET
    $APOP
    Medical/Dental Instruments
    Health Care
    Get the next $APOP alert in real time by email
    SC 13G 1 qnrx-sc13g_111221.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     
    Quoin Pharmaceuticals Ltd.

    (Name of Issuer)

     

     
     
    American Depository Shares

    (Title of Class of Securities)

     

     
     

     

    74907L102**

    (CUSIP Number)

     

     
     
    October 29, 2021
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    ** The CUSIP number is for the American Depository Shares that trade on the NASDAQ Global Market, each representing 400 Ordinary Shares. No CUSIP number has been assigned to the Ordinary Shares.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
    Page 2 of 8 

     

    CUSIP No.     74907L102    

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) x

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    833,773 American Depository Shares

    235,290 Escrow American Depository Shares(1)

    1,238,429 American Depository Shares issuable upon exercise of Exchange Warrants(2)

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    833,773 American Depository Shares

    235,290 Escrow American Depository Shares(1)

    1,238,429 American Depository Shares issuable upon exercise of Exchange Warrants(2)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    833,773 American Depository Shares

    235,290 Escrow American Depository Shares(1)

    1,238,429 American Depository Shares issuable upon exercise of Exchange Warrants(2)

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.99%(1)(2)(3)

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             

     

    (1)    As more fully described in Item 4, the shares of Escrow ADS are subject to a 9.99% Escrow Blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of ADS that would be held, if the ADS held in escrow were received. Therefore, the actual number of shares of ADS beneficially owned by each such Reporting Person, after giving effect to such Escrow Blocker is less than the number of securities reported in rows (6), (8) and (9).

     

    (2)    As more fully described in Item 4, the Exchange Warrants are subject to a Warrant Blocker of 4.99%. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of ADS that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such Warrant Blocker. Therefore, the actual number of ADS beneficially owned by each such Reporting Person, after giving effect to such Warrant Blocker, is less than the number of securities reported in rows (6), (8) and (9).

     

    (3)    Based on 8,346,077 American Depository Shares which represent 3,338,430,800 Ordinary Shares outstanding as of October 28, 2021, as set forth in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on October 29, 2021.

     

     

     
    Page 3 of 8 

     

    CUSIP No.   74907L102    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) x

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    833,773 American Depository Shares

    235,290 Escrow American Depository Shares(1)

    1,238,429 American Depository Shares issuable upon exercise of Exchange Warrants(2)

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    833,773 American Depository Shares

    235,290 Escrow American Depository Shares(1)

    1,238,429 American Depository Shares issuable upon exercise of Exchange Warrants(2)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    833,773 American Depository Shares

    235,290 Escrow American Depository Shares(1)

    1,238,429 American Depository Shares issuable upon exercise of Exchange Warrants(2)

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.99%(1)(2)(3)

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

    (1)    As more fully described in Item 4, the shares of Escrow ADS are subject to a 9.99% Escrow Blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of ADS that would be held, if the ADS held in escrow were received. Therefore, the actual number of shares of ADS beneficially owned by each such Reporting Person, after giving effect to such Escrow Blocker is less than the number of securities reported in rows (6), (8) and (9).

     

    (2)    As more fully described in Item 4, the Exchange Warrants are subject to a Warrant Blocker of 4.99%. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of ADS that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such Warrant Blocker. Therefore, the actual number of ADS beneficially owned by each such Reporting Person, after giving effect to such Warrant Blocker, is less than the number of securities reported in rows (6), (8) and (9).

     

    (3)    Based on 8,346,077 American Depository Shares which represent 3,338,430,800 Ordinary Shares outstanding as of October 28, 2021, as set forth in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on October 29, 2021.

     

     
    Page 4 of 8 

     

    CUSIP No.   74907L102    

     

    1

    NAME OF REPORTING PERSONS

    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) x

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    833,773 American Depository Shares

    235,290 Escrow American Depository Shares(1)

    1,238,429 American Depository Shares issuable upon exercise of Exchange Warrants(2)

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    833,773 American Depository Shares

    235,290 Escrow American Depository Shares(1)

    1,238,429 American Depository Shares issuable upon exercise of Exchange Warrants(2)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    833,773 American Depository Shares

    235,290 Escrow American Depository Shares(1)

    1,238,429 American Depository Shares issuable upon exercise of Exchange Warrants(2)

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.99%(1)(2)(3)

     
    12

    TYPE OF REPORTING PERSON

    OO

     

     


    (1)    As more fully described in Item 4, the shares of Escrow ADS are subject to a 9.99% Escrow Blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of ADS that would be held, if the ADS held in escrow were received. Therefore, the actual number of shares of ADS beneficially owned by each such Reporting Person, after giving effect to such Escrow Blocker is less than the number of securities reported in rows (6), (8) and (9).

     

    (2)    As more fully described in Item 4, the Exchange Warrants are subject to a Warrant Blocker of 4.99%. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of ADS that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such Warrant Blocker. Therefore, the actual number of ADS beneficially owned by each such Reporting Person, after giving effect to such Warrant Blocker, is less than the number of securities reported in rows (6), (8) and (9).

     

    (3)    Based on 8,346,077 American Depository Shares which represent 3,338,430,800 Ordinary Shares outstanding as of October 28, 2021, as set forth in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on October 29, 2021.

     

     

     
    Page 5 of 8 

     

    CUSIP No.  74907L102    

     

    Item 1(a). Name of Issuer:                                                          Quoin Pharmaceuticals Ltd.(the “Issuer”)
       
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:   23 Hata’as Street, Kfar Saba, Israel 44425
       
       
    Item 2(a).

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

       
       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
      The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
       
       
    Item 2(c). Citizenship:
      See Item 4 on the cover page(s) hereto.
       
       
    Item 2(d). Title of Class of Securities: American Depository Shares
       
       
       
    Item 2(e). CUSIP Number: 74907L102 assigned to the ADS. No CUSIP number has been assigned to the Ordinary Shares
       

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     
    Page 6 of 8 

     

    CUSIP No.   74907L102    

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person Based on 8,346,077 American Depository Shares which represent 3,338,430,800 Ordinary Shares outstanding as of October 28, 2021, as set forth in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on October 29, 2021. Each American Depository Share represents 400 Ordinary Shares of the Issuer.

     

    Pursuant to the terms of the securities purchase agreement entered into between the Fund and the Issuer, the Fund purchased American Depository Shares (“ADS”), American Depository Shares held in escrow (“Escrow ADS”) and Exchange Warrants. The Reporting Persons cannot exercise the Exchange Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding ADS (the “Warrant Blocker”). In addition, the Reporting Persons cannot receive the Escrow ADS to the extent the Reporting Persons would beneficially own more than 9.99% of the outstanding ADS (the “Escrow Blocker”) and together with the Warrant Blocker, the “Blockers”)). The percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to convert any of Exchange Warrants nor receive any Escrow ADS.

     

     

     
    Page 7 of 8 

     

    CUSIP No .   74907L102  

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ☐
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:           November 12, 2021  
       
    Altium Capital Management, LP  
       
    By: /s/ Jacob Gottlieb  
    Name: Jacob Gottlieb  
    Title: CEO  
           

     

     

    Altium Growth Fund, LP  
       

    By:   Altium Growth GP, LLC

    Its:   General Partner

     
       
    Signature:  /s/ Jacob Gottlieb  
    Name: Jacob Gottlieb  
    Title: Managing Member of Altium Growth GP, LLC
           

     

     

    Altium Growth GP, LLC  
       
    By: /s/ Jacob Gottlieb  
    Name: Jacob Gottlieb  
    Title: Managing Member  
           

     

     
    Page 8 of 8 

     

    EXHIBIT INDEX

     

     

    EXHIBIT 1:            Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

    Members of Group

     

     

     

     
    Get the next $APOP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APOP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APOP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cellect Biotechnology Ltd.

    SC 13G - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/12/21 2:20:55 PM ET
    $APOP
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Cellect Biotechnology Ltd. (0001671502) (Subject)

    2/16/21 9:42:27 AM ET
    $APOP
    Medical/Dental Instruments
    Health Care

    $APOP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals

    Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP") (the "Company"), announced today the record date and distribution date for the contingent value rights (the "CVRs") to be distributed in connection with the previously announced strategic merger with privately-held Quoin Pharmaceuticals, Inc., a specialty pharmaceutical company focused on rare and orphan diseases (the "Merger") and the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd., to EnCellX, Inc., a privately held company based in San Diego, CA (the "Share Transfer").  Upon the closings of the Merger and Share Transfer, the Depositary for the Company's American Depositary Shar

    10/15/21 4:01:00 PM ET
    $APOP
    Medical/Dental Instruments
    Health Care

    Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

    Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held Quoin Pharmaceuticals, a specialty pharmaceutical company focused on rare and orphan diseases, and all other proposals presented at the Special General Meeting of shareholders held on September 26, 2021, including the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd, to EnCellX Inc. , a privately held company based in San Diego, CA.  Approximately 99% of the votes cast on the strategic merger agreement at the Special General Meeting voted in favor of approving the proposal. The

    9/27/21 9:10:00 AM ET
    $APOP
    Medical/Dental Instruments
    Health Care

    Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.

    Tel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company's clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company's cell selection technology designed to optimize immune therapy, in this application - prevent graft-versus-host disease (GVHD) following bone marrow transplantation. Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraftTM development will be pursued by EnCellX, the privately held U.S. based company that

    9/2/21 4:20:00 PM ET
    $APOP
    Medical/Dental Instruments
    Health Care

    $APOP
    SEC Filings

    View All

    SEC Form 6-K filed by Cellect Biotechnology Ltd.

    6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    12/17/21 7:47:17 PM ET
    $APOP
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Cellect Biotechnology Ltd.

    6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    11/23/21 5:07:16 PM ET
    $APOP
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Cellect Biotechnology Ltd.

    6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    10/29/21 9:31:01 AM ET
    $APOP
    Medical/Dental Instruments
    Health Care